FDA continues to issue a large number of complete response letters for generic drug applications, and the first-cycle ANDA approval rate could get worse before it gets better as the first generation of the Generic Drug User Fee Act nears expiration, agency officials said.
While agency staff speaking at the Generic Pharmaceutical Association’s Fall Technical Conference Oct